Sanofi (SNY) Competitors

Sanofi (NASDAQ:SNY) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Which has stronger valuation and earnings, SNY or NVS?

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$44.46B	2.71	$6.02B	$4.16	11.79
Novartis	$50.32B	5.13	$11.94B	$6.87	17.79

Does the media prefer SNY or NVS?

In the previous week, Novartis had 11 more articles in the media than Sanofi. MarketBeat recorded 29 mentions for Novartis and 18 mentions for Sanofi. Novartis' average media sentiment score of 1.17 beat Sanofi's score of 0.77 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	8 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	15 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is SNY or NVS a better dividend stock?

Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.3%. Novartis pays an annual dividend of $2.60 per share and has a dividend yield of 2.1%. Sanofi pays out 38.5% of its earnings in the form of a dividend. Novartis pays out 37.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Is SNY or NVS more profitable?

Novartis has a net margin of 25.64% compared to Sanofi's net margin of 21.47%. Novartis' return on equity of 41.08% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	21.47%	16.86%	9.63%
Novartis	25.64%	41.08%	16.83%

Do analysts recommend SNY or NVS?

Sanofi presently has a consensus price target of $62.00, indicating a potential upside of 26.43%. Novartis has a consensus price target of $123.50, indicating a potential upside of 1.03%. Given Sanofi's stronger consensus rating and higher possible upside, equities research analysts plainly believe Sanofi is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.11
Novartis	2 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.09

Do insiders & institutionals believe in SNY or NVS?

14.0% of Sanofi shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more volatility and risk, SNY or NVS?

Sanofi has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.

Summary

Novartis beats Sanofi on 12 of the 19 factors compared between the two stocks.